US FDA Advisory Cmte. Review Of Charleston's Hydexor Exposes Flaws In Commercial Strategy
Executive Summary
Physicians may be hesitant to prescribe the opioid/anti-emetic combo for several reasons; panelists were concerned the company hasn't figured out a specific commercial audience for Hydexor at this point in the review process.